

Anders Jakobsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8191240/publications.pdf>

Version: 2024-02-01

124
papers

5,037
citations

126907

33
h-index

102487

66
g-index

125
all docs

125
docs citations

125
times ranked

7477
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases – a report from the Danish Anal Cancer Group. <i>Acta Oncologica</i> , 2022, 61, 321-327. | 1.8 | 1 |
| 2 | Reporting on circulating tumor DNA monitoring in metastatic cancer – From clinical validity to clinical utility. <i>Cancer</i> , 2022, 128, 2052-2057. | 4.1 | 7 |
| 3 | Prognostic Impact of Circulating Methylated Homeobox A9 DNA in Patients Undergoing Treatment for Recurrent Ovarian Cancer. <i>Cancers</i> , 2022, 14, 1766. | 3.7 | 6 |
| 4 | The Prognostic Importance of ctDNA in Rectal Cancer: A Critical Reappraisal. <i>Cancers</i> , 2022, 14, 2252. | 3.7 | 8 |
| 5 | Cell Free Methylated Tumor DNA in Bronchial Lavage as an Additional Tool for Diagnosing Lung Cancer – A Systematic Review. <i>Cancers</i> , 2022, 14, 2254. | 3.7 | 1 |
| 6 | Natural killer cell activity as a biomarker for the diagnosis of lung cancer in high-risk patients. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211089. | 1.0 | 3 |
| 7 | Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: a retrospective, international, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 43-50. | 10.7 | 122 |
| 8 | The prognostic impact of circulating homeobox A9 methylated DNA in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 855-865. | 2.8 | 7 |
| 9 | Early ctDNA response to chemotherapy. A potential surrogate marker for overall survival. <i>European Journal of Cancer</i> , 2021, 149, 128-133. | 2.8 | 20 |
| 10 | Long-term anorectal function in rectal cancer patients treated with chemoradiotherapy and endorectal brachytherapy. <i>Colorectal Disease</i> , 2021, 23, 2311-2319. | 1.4 | 8 |
| 11 | Intensified Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Anus – A Population-Based Experience from the Danish Anal Cancer Group. <i>Cancers</i> , 2021, 13, 3226. | 3.7 | 3 |
| 12 | Validating Methylated HOXA9 in Bronchial Lavage as a Diagnostic Tool in Patients Suspected of Lung Cancer. <i>Cancers</i> , 2021, 13, 4223. | 3.7 | 3 |
| 13 | Performance of the EarlyCDT® Lung test in detection of lung cancer and pulmonary metastases in a high-risk cohort. <i>Lung Cancer</i> , 2021, 158, 85-90. | 2.0 | 13 |
| 14 | Analysis of HOXA9 methylated ctDNA in ovarian cancer using sense-antisense measurement. <i>Clinica Chimica Acta</i> , 2021, 522, 152-157. | 1.1 | 7 |
| 15 | Circulating HOXA9-methylated tumour DNA: A novel biomarker of response to poly (ADP-ribose) polymerase inhibition in BRCA-mutated epithelial ovarian cancer. <i>European Journal of Cancer</i> , 2020, 125, 121-129. | 2.8 | 32 |
| 16 | Long-Term Patient-Reported Outcomes After High-Dose Chemoradiation Therapy for Nonsurgical Management of Distal Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 556-563. | 0.8 | 32 |
| 17 | Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers. <i>Acta Oncologica</i> , 2020, 59, 298-301. | 1.8 | 3 |
| 18 | Carboplatin re-treatment in platinum-resistant epithelial ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 751-759. | 2.3 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Evaluation of the stage classification of anal cancer by the TNM 8th version versus the TNM 7th version. <i>Acta Oncologica</i> , 2020, 59, 1016-1023. | 1.8 | 8 |
| 20 | Blood natural killer cells during treatment in recurrent ovarian cancer. <i>Acta Oncologica</i> , 2020, 59, 1365-1373. | 1.8 | 7 |
| 21 | Cabazitaxel - A Treatment Option in Recurrent Platinum-resistant Ovarian Cancer. <i>Anticancer Research</i> , 2020, 40, 5255-5261. | 1.1 | 3 |
| 22 | Comparison of Mutated KRAS and Methylated HOXA9 Tumor-Specific DNA in Advanced Lung Adenocarcinoma. <i>Cancers</i> , 2020, 12, 3728. | 3.7 | 6 |
| 23 | Decreased concentrations of intracellular signaling proteins in colon cancer patients with BRAF mutations. <i>Scientific Reports</i> , 2020, 10, 20113. | 3.3 | 5 |
| 24 | The Clinical Impact of MicroRNA-21 in Low Rectal Cancer Treated with High-Dose Chemoradiotherapy in the Organ Preserving Setting. <i>Gastrointestinal Disorders</i> , 2020, 2, 378-384. | 0.8 | 0 |
| 25 | Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. <i>Journal of Ovarian Research</i> , 2020, 13, 59. | 3.0 | 13 |
| 26 | Prognostic Value of Serum NPY Hypermethylation in Neoadjuvant Chemoradiotherapy for Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 9-13. | 1.3 | 15 |
| 27 | Early identification of treatment benefit by methylated circulating tumor DNA in metastatic colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592091847. | 3.2 | 26 |
| 28 | Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. <i>Acta Oncologica</i> , 2020, 59, 652-659. | 1.8 | 28 |
| 29 | Circulating tumor-specific DNA: a stony road to clinical utility. <i>Biomarkers in Medicine</i> , 2020, 14, 331-333. | 1.4 | 0 |
| 30 | NPY Gene Methylation as a Universal, Longitudinal Plasma Marker for Evaluating the Clinical Benefit from Last-Line Treatment with Regorafenib in Metastatic Colorectal Cancer. <i>Cancers</i> , 2019, 11, 1649. | 3.7 | 17 |
| 31 | Correlation Between Natural Killer Cell Activity and Treatment Effect in Patients with Disseminated Cancer. <i>Translational Oncology</i> , 2019, 12, 968-972. | 3.7 | 15 |
| 32 | The clinical importance of BRCAness in a population-based cohort of Danish epithelial ovarian cancer. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 166-173. | 2.5 | 17 |
| 33 | Correlation Between Tumor-Specific Mutated and Methylated DNA in Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-8. | 3.0 | 7 |
| 34 | Delta tocotrienol in recurrent ovarian cancer. A phase II trial. <i>Pharmacological Research</i> , 2019, 141, 392-396. | 7.1 | 47 |
| 35 | Plasma Dynamics of RAS/RAF Mutations in Patients With Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-EGFR Treatment. <i>Clinical Colorectal Cancer</i> , 2019, 18, 28-33.e3. | 2.3 | 9 |
| 36 | MicroRNA-126 and epidermal growth factor-like domain 7 predict recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. , 2019, 2, 885-896. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 37 | Quantification of NK cell activity using whole blood: Methodological aspects of a new test. <i>Journal of Immunological Methods</i> , 2018, 458, 21-25. | 1.4 | 20 |
| 38 | Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. <i>Cancer Treatment and Research Communications</i> , 2018, 14, 7-12. | 1.7 | 16 |
| 39 | Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohorts. <i>British Journal of Cancer</i> , 2018, 119, 1367-1373. | 6.4 | 30 |
| 40 | Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. <i>Lancet</i> , The, 2018, 391, 2537-2545. | 13.7 | 677 |
| 41 | Tumor stroma ratio predicts recurrence in patients with colon cancer treated with neoadjuvant chemotherapy. <i>Acta Oncologica</i> , 2018, 57, 528-533. | 1.8 | 36 |
| 42 | Analysis of a gene panel for targeted sequencing of colorectal cancer samples. <i>Oncotarget</i> , 2018, 9, 9043-9060. | 1.8 | 8 |
| 43 | Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab. <i>Scientific Reports</i> , 2017, 7, 2388. | 3.3 | 18 |
| 44 | The prognostic value of simultaneous tumor and serum RAS/RAF mutations in localized colon cancer. <i>Cancer Medicine</i> , 2017, 6, 928-936. | 2.8 | 15 |
| 45 | The Prognostic Value of BRCA1 and PARP Expression in Epithelial Ovarian Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017, 36, 180-189. | 1.4 | 28 |
| 46 | Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1842-1849. | 2.5 | 33 |
| 47 | Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. <i>Oncologist</i> , 2017, 22, 1049-1055. | 3.7 | 73 |
| 48 | Association between the expression of microRNAs and the response of patients with locally advanced rectal cancer to preoperative chemoradiotherapy. <i>Oncology Letters</i> , 2017, 14, 201-209. | 1.8 | 19 |
| 49 | MicroRNA Expression Profiling to Identify and Validate Reference Genes for the Relative Quantification of microRNA in Rectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0150593. | 2.5 | 32 |
| 50 | Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. <i>Oncology Letters</i> , 2016, 11, 3967-3974. | 1.8 | 13 |
| 51 | Screening for circulating RAS/RAF mutations by multiplex digital PCR. <i>Clinica Chimica Acta</i> , 2016, 458, 138-143. | 1.1 | 37 |
| 52 | The Prognostic Value of Plasma YKL-40 in Patients With Chemotherapy-Resistant Ovarian Cancer Treated With Bevacizumab. <i>International Journal of Gynecological Cancer</i> , 2016, 26, 1390-1398. | 2.5 | 19 |
| 53 | Intratumoral Heterogeneity of MicroRNA Expression in Rectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0156919. | 2.5 | 16 |
| 54 | Circulating Free DNA as Biomarker and Source for Mutation Detection in Metastatic Colorectal Cancer. <i>PLoS ONE</i> , 2015, 10, e0108247. | 2.5 | 109 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | TIMP-1 and CEA as biomarkers in third-line treatment with irinotecan and cetuximab for metastatic colorectal cancer. <i>Tumor Biology</i> , 2015, 36, 4301-4308. | 1.8 | 7 |
| 56 | Intra-tumoural vessel area estimated by expression of epidermal growth factor-like domain 7 and microRNA-126 in primary tumours and metastases of patients with colorectal cancer: a descriptive study. <i>Journal of Translational Medicine</i> , 2015, 13, 10. | 4.4 | 15 |
| 57 | High-dose chemoradiotherapy and watchful waiting for distal rectal cancer: a prospective observational study. <i>Lancet Oncology</i> , The, 2015, 16, 919-927. | 10.7 | 435 |
| 58 | Controls to validate plasma samples for cell free DNA quantification. <i>Clinica Chimica Acta</i> , 2015, 446, 141-146. | 1.1 | 63 |
| 59 | Neoadjuvant chemotherapy in locally advanced colon cancer. A phase II trial. <i>Acta OncolÃ³gica</i> , 2015, 54, 1747-1753. | 1.8 | 84 |
| 60 | Elastography and diffusion-weighted MRI in patients with rectal cancer. <i>British Journal of Radiology</i> , 2015, 88, 20150294. | 2.2 | 10 |
| 61 | Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy. <i>European Journal of Cancer</i> , 2015, 51, 2678-2685. | 2.8 | 48 |
| 62 | Radiation Techniques for Increasing Local Control in the Non-Surgical Management of Rectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015, 11, 267-274. | 0.5 | 2 |
| 63 | Improved sensitivity of circulating tumor DNA measurement using short PCR amplicons. <i>Clinica Chimica Acta</i> , 2015, 439, 97-101. | 1.1 | 33 |
| 64 | Dose-response of acute urinary toxicity of long-course preoperative chemoradiotherapy for rectal cancer. <i>Acta OncolÃ³gica</i> , 2015, 54, 179-186. | 1.8 | 25 |
| 65 | Functional Screening Identifies miRNAs Influencing Apoptosis and Proliferation in Colorectal Cancer. <i>PLoS ONE</i> , 2014, 9, e96767. | 2.5 | 49 |
| 66 | Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: The prediction value of ERCC1 and Tau expression. <i>International Journal of Oncology</i> , 2014, 44, 1736-1744. | 3.3 | 25 |
| 67 | Anal carcinoma â€œ Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. <i>Radiotherapy and Oncology</i> , 2014, 113, 352-358. | 0.6 | 49 |
| 68 | Epidermal Growth Factorâ€œlike Domain 7 Predicts Response to First-Line Chemotherapy and Bevacizumab in Patients with Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2238-2245. | 4.1 | 17 |
| 69 | The prognostic value of microRNA-126 and microvessel density in patients with stage II colon cancer: results from a population cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 254. | 4.4 | 17 |
| 70 | Less extensive surgery compared to extensive surgery: survival seems similar in young women with adult ovarian granulosa cell tumor. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 177, 61-66. | 1.1 | 4 |
| 71 | Changes in mutational status during thirdâ€œline treatment for metastatic colorectal cancerâ€œResults of consecutive measurement of cell free DNA, <i>KRAS</i> and <i>BRAF</i> in the plasma. <i>International Journal of Cancer</i> , 2014, 135, 2215-2222. | 5.1 | 76 |
| 72 | Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer. <i>International Journal of Cancer</i> , 2014, 135, 2984-2991. | 5.1 | 94 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Prognostic importance of cell-free DNA in chemotherapy resistant ovarian cancer treated with bevacizumab. <i>European Journal of Cancer</i> , 2014, 50, 2611-2618. | 2.8 | 50 |
| 74 | Selection of colon cancer patients for neoadjuvant chemotherapy by preoperative CT scan. <i>Scandinavian Journal of Gastroenterology</i> , 2014, 49, 202-208. | 1.5 | 44 |
| 75 | Long-Term Results of a Randomized Trial in Locally Advanced Rectal Cancer: No Benefit From Adding a Brachytherapy Boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 110-118. | 0.8 | 46 |
| 76 | Levels of cell-free DNA and plasma KRAS during treatment of advanced NSCLC. <i>Oncology Reports</i> , 2014, 31, 969-974. | 2.6 | 34 |
| 77 | Visualising and quantifying angiogenesis in metastatic colorectal cancer. <i>Cellular Oncology (Dordrecht)</i> , 2013, 36, 341-350. | 4.4 | 14 |
| 78 | The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2013, 79, 312-317. | 2.0 | 101 |
| 79 | Immunohistological expression of HIF-1 α , GLUT-1, Bcl-2 and K α 67 in consecutive biopsies during chemoradiotherapy in patients with rectal cancer. <i>Apmis</i> , 2013, 121, 127-138. | 2.0 | 10 |
| 80 | In Reply to Fekete. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 213. | 0.8 | 1 |
| 81 | The Influence of Tissue Ischemia on Biomarker Expression in Colorectal Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2013, 21, 298-307. | 1.2 | 10 |
| 82 | Tumour hypoxia imaging with 18F-fluoroazomycinarabinofuranoside PET/CT in patients with locally advanced rectal cancer. <i>Nuclear Medicine Communications</i> , 2013, 34, 155-161. | 1.1 | 34 |
| 83 | Panitumumab and Pegylated Liposomal Doxorubicin in Platinum-Resistant Epithelial Ovarian Cancer With KRAS Wild-Type: The PaLiDo Study, a Phase II Nonrandomized Multicenter Study. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 73-80. | 2.5 | 21 |
| 84 | Immunohistochemical Expression of Platelet-Derived Growth Factor Receptors in Ovarian Cancer Patients with Long-Term Follow-Up. <i>Pathology Research International</i> , 2012, 2012, 1-8. | 1.4 | 10 |
| 85 | The Prognostic and Predictive Value of Combined HE4 and CA-125 in Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 1474-1482. | 2.5 | 23 |
| 86 | Transrectal ultrasound and magnetic resonance imaging measurement of extramural tumor spread in rectal cancer. <i>World Journal of Gastroenterology</i> , 2012, 18, 5021. | 3.3 | 21 |
| 87 | Single nucleotide polymorphisms in the HIF-1 α gene and chemoradiotherapy of locally advanced rectal cancer. <i>Oncology Letters</i> , 2012, 4, 1056-1060. | 1.8 | 7 |
| 88 | Dose-Effect Relationship in Chemoradiotherapy for Locally Advanced Rectal Cancer: A Randomized Trial Comparing Two Radiation Doses. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 949-954. | 0.8 | 100 |
| 89 | Serial measurements of serum PDGF-AA, PDGF-BB, FGF2, and VEGF in multiresistant ovarian cancer patients treated with bevacizumab. <i>Journal of Ovarian Research</i> , 2012, 5, 23. | 3.0 | 29 |
| 90 | Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan. <i>Clinical Cancer Research</i> , 2012, 18, 1177-1185. | 7.0 | 244 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. <i>Pharmacogenomics</i> , 2012, 13, 763-770. | 1.3 | 16 |
| 92 | The predictive value of single nucleotide polymorphisms in the VEGF system to the efficacy of first-line treatment with bevacizumab plus chemotherapy in patients with metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2012, 27, 715-720. | 2.2 | 49 |
| 93 | Limitations of tissue micro array in Duke's B colon cancer. <i>Apmis</i> , 2012, 120, 819-827. | 2.0 | 2 |
| 94 | The predictive value of microRNA-126 in relation to first line treatment with capecitabine and oxaliplatin in patients with metastatic colorectal cancer. <i>BMC Cancer</i> , 2012, 12, 83. | 2.6 | 51 |
| 95 | A Phase II dose escalation study of fixed-dose rate gemcitabine, oxaliplatin and capecitabine every two weeks in advanced cholangiocarcinomas. <i>Acta Oncologica</i> , 2011, 50, 448-454. | 1.8 | 17 |
| 96 | Clinical implications of genetic variations in the VEGF system in relation to colorectal cancer. <i>Pharmacogenomics</i> , 2011, 12, 1681-1693. | 1.3 | 24 |
| 97 | The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2011, 4, 12-18. | 0.2 | 3 |
| 98 | Prognostic Impact of Prechemotherapy Serum Levels of HER2, CA125, and HE4 in Ovarian Cancer Patients. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1040-1047. | 2.5 | 44 |
| 99 | Prevalence of Epithelial Ovarian Cancer Stem Cells Correlates with Recurrence in Early-Stage Ovarian Cancer. <i>Journal of Oncology</i> , 2011, 2011, 1-12. | 1.3 | 74 |
| 100 | Elevated microRNA-126 is associated with high vascular endothelial growth factor receptor 2 expression levels and high microvessel density in colorectal cancer. <i>Oncology Letters</i> , 2011, 2, 1101-1106. | 1.8 | 24 |
| 101 | EGFR related mutational status and association to clinical outcome of third-line cetuximab-irinotecan in metastatic colorectal cancer. <i>BMC Cancer</i> , 2011, 11, 107. | 2.6 | 19 |
| 102 | Improved Classification of Epithelial Ovarian Cancer: Results of 3 Danish Cohorts. <i>International Journal of Gynecological Cancer</i> , 2011, 21, 1592-1600. | 2.5 | 32 |
| 103 | Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIg). <i>International Journal of Gynecological Cancer</i> , 2011, 21, 419-423. | 2.5 | 500 |
| 104 | Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 589-600. | 2.4 | 10 |
| 105 | Microvessel density and the association with single nucleotide polymorphisms of the vascular endothelial growth factor receptor 2 in patients with colorectal cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2010, 456, 251-260. | 2.8 | 42 |
| 106 | The importance of 460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2010, 136, 751-758. | 2.5 | 24 |
| 107 | Lack of relationship between TIMP-1 tumour cell immunoreactivity, treatment efficacy and prognosis in patients with advanced epithelial ovarian cancer. <i>BMC Cancer</i> , 2010, 10, 185. | 2.6 | 7 |
| 108 | The Prognostic Value of Haplotypes in the Vascular Endothelial Growth Factor A Gene in Colorectal Cancer. <i>Cancers</i> , 2010, 2, 1405-1418. | 3.7 | 9 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | The Relationship of Platinum Resistance and ERCC1 Protein Expression in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 820-825. | 2.5 | 68 |
| 110 | Protein kinase C-beta II (PKC- β II) expression in patients with colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2009, 24, 641-645. | 2.2 | 11 |
| 111 | Prognostic Importance of Vascular Endothelial Growth Factor-A Expression and Vascular Endothelial Growth Factor Polymorphisms in Epithelial Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 578-584. | 2.5 | 27 |
| 112 | PET/CT and Histopathologic Response to Preoperative Chemoradiation Therapy in Locally Advanced Rectal Cancer. <i>Diseases of the Colon and Rectum</i> , 2008, 51, 21-25. | 1.3 | 77 |
| 113 | A COX-2 inhibitor combined with chemoradiation of locally advanced rectal cancer: a phase II trial. <i>International Journal of Colorectal Disease</i> , 2008, 23, 251-255. | 2.2 | 24 |
| 114 | The prognostic importance of thymidylate gene polymorphism in colon cancer stage II. <i>International Journal of Colorectal Disease</i> , 2008, 23, 1267-1267. | 2.2 | 0 |
| 115 | Preoperative Serum Levels of Epidermal Growth Factor Receptor, HER2, and Vascular Endothelial Growth Factor in Malignant and Benign Ovarian Tumors. <i>Clinical Ovarian Cancer & Other Gynecologic Malignancies</i> , 2008, 1, 127-134. | 0.2 | 4 |
| 116 | Microsatellite Instability and the Association with Plasma Homocysteine and Thymidylate Synthase in Colorectal Cancer. <i>Cancer Investigation</i> , 2008, 26, 583-589. | 1.3 | 12 |
| 117 | Mutant Epidermal Growth Factor Receptor in Benign, Borderline, and Malignant Ovarian Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 3278-3282. | 7.0 | 26 |
| 118 | Transrectal ultrasonography and magnetic resonance imaging in the staging of rectal cancer. Effect of experience. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 440-446. | 1.5 | 31 |
| 119 | Epidermal growth factor (EGF) A61G polymorphism and EGF gene expression in normal colon tissue from patients with colorectal cancer. <i>Acta Oncologica</i> , 2007, 46, 1113-1117. | 1.8 | 34 |
| 120 | Germline Polymorphisms may Act as Predictors of Response to Preoperative Chemoradiation in Locally Advanced T3 Rectal Tumors. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 1363-1369. | 1.3 | 36 |
| 121 | Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 461-465. | 0.8 | 60 |
| 122 | Report of an Early Stopped Randomized Trial Comparing Cisplatin vs. Cisplatin/Ifosfamide/5-Fluorouracil in Recurrent Cervical Cancer. <i>Gynecologic and Obstetric Investigation</i> , 2005, 59, 126-129. | 1.6 | 18 |
| 123 | Granulosa Cell Tumor of the Ovary: A Population-Based Study of 37 Women with Stage I Disease. <i>Gynecologic Oncology</i> , 2001, 81, 456-460. | 1.4 | 100 |
| 124 | A Phase II Trial of Ifosfamide, 5-Fluorouracil, and Leucovorin in Recurrent Uterine Cervical Cancer. <i>Gynecologic Oncology</i> , 1994, 55, 123-125. | 1.4 | 10 |